Results 11 to 20 of about 33,449 (240)

Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database

open access: yesFrontiers in Psychiatry, 2022
3,4-Methylenedioxymethamphetamine (MDMA), is investigated as a treatment for post-traumatic stress disorder and other anxiety-related conditions in multiple placebo-controlled and open label studies. MDMA-assisted therapy is projected for approval by the
Tigran Makunts   +4 more
doaj   +1 more source

Differential effects of MDMA and methylphenidate on social cognition [PDF]

open access: yes, 2014
Social cognition is important in everyday-life social interactions. The social cognitive effects of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and methylphenidate (both used for neuroenhancement and as party drugs) are largely unknown.
Crockett, Molly J.   +5 more
core   +1 more source

Mice in ecstasy : advanced animal models in the study of MDMA [PDF]

open access: yes, 2010
The party drug 3,4-methylenedioxymethamphetamine -better known as MDMA or ecstasy- has numerous effects on the human body, characterized by a rush of energy, euphoria and empathy.
Stove, Christophe   +3 more
core   +2 more sources

Zinc Protects against MDMA-Induced Apoptosis of Sertoli Cells in Mouse via Attenuation of Caspase-3 [PDF]

open access: yesInternational Journal of Fertility and Sterility, 2020
Background: 3,4-Methylenedioxymethamphetamine (MDMA) disrupts function of the endocrine system and differentorgans such as heart, blood vessels, kidney, liver and nervous systems.
Nadia Hossein-Zadeh   +4 more
doaj   +1 more source

Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. [PDF]

open access: yesPLoS ONE, 2012
This study assessed the effects of the serotonin (5-HT) and norepinephrine (NE) transporter inhibitor duloxetine on the effects of 3,4-methylenedioxy-methamphetamine (MDMA, ecstasy) in vitro and in 16 healthy subjects.
Cédric M Hysek   +9 more
doaj   +1 more source

Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects

open access: yesFrontiers in Pharmacology, 2022
Background: 3,4-Methylenedioxymethamphetamine (MDMA) has shown initial promise as an adjunct in psychotherapy to treat posttraumatic stress disorder (PTSD). Its efficacy and safety have been demonstrated across phase I–III studies. However, the mechanism
Patrick Vizeli   +15 more
doaj   +1 more source

Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users [PDF]

open access: yes, 2002
The recreational use of MDMA/Ecstasy (3,4-methylenedioxymethamphetamine) is associated with many psychobiological problems, but there is a paucity of data on how these relate to the level of past use.
Curran   +23 more
core   +2 more sources

The use of 3,4-Methylenedioxymethamphetamine (MDMA) in the treatment of Post-Traumatic Stress Disorder (PTSD) - review

open access: yesJournal of Education, Health and Sport, 2023
Introduction: Post-traumatic stress disorder (PTSD) is a common health issue of complex etiology significantly deteriorating functioning in everyday life. It may develop as a result of exposure to traumatic events like traffic accidents, war experience,
Karol Womperski   +6 more
doaj   +1 more source

MDMA Powder, Pills and Crystal: The persistance of ecstasy and the poverty of policy. [PDF]

open access: yes, 2009
Commonly known as ecstasy, MDMA has been central to the British acid house, rave and dance club scene over the last 20 years. Figures from the annual national British Crime Survey suggest that ecstasy use has declined since 2001. This apparent decline is
Measham, Fiona   +2 more
core   +1 more source

Aromatic Bromination Abolishes the Psychomotor Features and Pro-social Responses of MDMA (“Ecstasy”) in Rats and Preserves Affinity for the Serotonin Transporter (SERT)

open access: yesFrontiers in Pharmacology, 2019
The entactogen MDMA (3,4-methylenedioxy-methamphetamine, “Ecstasy”) exerts its psychotropic effects acting primarily as a substrate of the serotonin transporter (SERT) to induce a non-exocytotic release of serotonin.
Patricio Sáez-Briones   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy